Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.
Level 1 - systematic review of randomized trials
Evidence-based clinical practice guideline synthesizing 52 systematic reviews across prioritized clinical questions.
PubMed 37589624 · doi:10.1016/j.fertnstert.2023.07.025
What was done
An international multidisciplinary panel representing 39 professional and consumer organizations across 71 countries updated the 2018 Polycystic Ovary Syndrome (PCOS) guideline. The update applied AGREE II and GRADE frameworks to address 58 prioritized clinical questions via 52 systematic and 3 narrative reviews conducted over 12 months across 20 meetings and five forums, with formal approval from the Australian National Health and Medical Research Council.
What was found
The guideline produced 254 guidance items: 77 evidence-based recommendations, 54 consensus recommendations, and 123 practice points. Key updates include: refining adult diagnostic criteria to permit anti-Müllerian hormone (AMH) levels as an alternative to ovarian ultrasound; expanding recognition of broader risks including cardiovascular disease, metabolic factors, sleep apnea, high prevalence of psychological features, and adverse pregnancy outcomes; addressing weight stigma; and prioritizing evidence-based medical therapy and lower-cost, safer fertility management. The abstract reports that the overall evidence quality across the field remains low to moderate and reports no numerical outcome statistics or effect sizes.
Why it matters
This guideline provides an updated, globally adopted standard of care for PCOS that formally integrates AMH into adult diagnostic algorithms and emphasizes psychological, metabolic, and fertility management beyond isolated gynecologic symptoms.
Limits
The underlying evidence base for most clinical questions remains low to moderate in quality, requiring 54 consensus recommendations and 123 practice points where rigorous trial data were unavailable. The abstract summary does not report specific quantitative metrics, cutoffs for AMH, or effect estimates for individual interventions.